Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

Registry ID

EUCTR2015-003527-57

Source registry

EUCTR

Phase

PHASE2

Sponsor

Novartis Pharmaceuticals

Last update

2026-08-16

Conditions

• Familial Mediterranean Fever

Summary

to measure the effect of canakinumab on the frequency of FMF attacks defined as percentage of subjects with at least 50% reduction in the attack frequency during 3 month treatment period.

Related clinical trials

• A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
• Outcomes of Inspiratory Muscle Training in FMF Adolescents
• Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise
• is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever
• Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks
• Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

View on source registry